WO2023154904A3 - Compositions and methods for treating acute myeloid leukemia - Google Patents

Compositions and methods for treating acute myeloid leukemia Download PDF

Info

Publication number
WO2023154904A3
WO2023154904A3 PCT/US2023/062447 US2023062447W WO2023154904A3 WO 2023154904 A3 WO2023154904 A3 WO 2023154904A3 US 2023062447 W US2023062447 W US 2023062447W WO 2023154904 A3 WO2023154904 A3 WO 2023154904A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
myeloid leukemia
acute myeloid
treating acute
Prior art date
Application number
PCT/US2023/062447
Other languages
French (fr)
Other versions
WO2023154904A2 (en
Inventor
Yi XU (David)
Huynh CAO
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loma Linda University filed Critical Loma Linda University
Publication of WO2023154904A2 publication Critical patent/WO2023154904A2/en
Publication of WO2023154904A3 publication Critical patent/WO2023154904A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are compositions and methods of treating AML in a subject by administering a TKI in combination with one or more of active vitamin D (such as, 1,25VD3), an expression construct encoding fructose-bisphosphatase 1 (FBP1) and protein phosphatase 2 catalytic subunit alpha (PPP2CA) or a cell containing thereof, and/or a tumor infiltrating lymphocyte (TIL) expressing a chimeric antigen receptor (CAR) targeting CXCR2 and/or CD33 to the subject. Also provided herein are compositions and methods of reducing viability and/or proliferation of an AML cell.
PCT/US2023/062447 2022-02-11 2023-02-11 Compositions and methods for treating acute myeloid leukemia WO2023154904A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263267891P 2022-02-11 2022-02-11
US63/267,891 2022-02-11

Publications (2)

Publication Number Publication Date
WO2023154904A2 WO2023154904A2 (en) 2023-08-17
WO2023154904A3 true WO2023154904A3 (en) 2023-09-21

Family

ID=87565167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/062447 WO2023154904A2 (en) 2022-02-11 2023-02-11 Compositions and methods for treating acute myeloid leukemia

Country Status (1)

Country Link
WO (1) WO2023154904A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2021188387A1 (en) * 2020-03-16 2021-09-23 Celgene Corporation Combination therapy for acute myeloid leukemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2021188387A1 (en) * 2020-03-16 2021-09-23 Celgene Corporation Combination therapy for acute myeloid leukemia

Also Published As

Publication number Publication date
WO2023154904A2 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
Jin et al. CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Abel et al. Natural killer cells: development, maturation, and clinical utilization
Keppel et al. Activation-specific metabolic requirements for NK Cell IFN-γ production
Suliman et al. A new activating role for CO in cardiac mitochondrial biogenesis
Becker-Hapak et al. A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy
Lee et al. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody
Hoebertz et al. Regulation of bone resorption and formation by purines and pyrimidines
Katano et al. Predominant development of mature and functional human NK cells in a novel human IL-2–producing transgenic NOG mouse
Helms et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy
Fathi et al. Interleukin-6,-8, and TGF-β secreted from mesenchymal stem cells show functional role in reduction of telomerase activity of leukemia cell via Wnt5a/β-catenin and P53 pathways
Maestroni Neurohormones and catecholamines as functional components of the bone marrow microenvironment
Pillet et al. A programmed switch from IL-15-to IL-2-dependent activation in human NK cells
Lv et al. Scutellarin inhibits hypoxia‐induced epithelial‐mesenchymal transition in bladder cancer cells
Pesce et al. Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes
Sarhan et al. Dendritic cell regulation of NK‐cell responses involves lymphotoxin‐α, IL‐12, and TGF‐β
Zhang et al. Inflammation-induced inhibition of chaperone-mediated autophagy maintains the immunosuppressive function of murine mesenchymal stromal cells
Hasegawa et al. Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia
Shao et al. TIGIT induces (CD3+) T cell dysfunction in colorectal cancer by inhibiting glucose metabolism
Sabri et al. Crosstalk of EGF‐directed MAPK signalling pathways and its potential role on EGF‐induced cell proliferation and COX‐2 expression in human mesenchymal stem cells
Seitz et al. Immunomonitoring of stage IV relapsed neuroblastoma patients undergoing haploidentical hematopoietic stem cell transplantation and subsequent GD2 (ch14. 18/CHO) antibody treatment
Kaneda et al. Cyclolinopeptide F, a cyclic peptide from flaxseed inhibited RANKL-induced osteoclastogenesis via downergulation of RANK expression
Zhou et al. Neuropathy and inflammation in diabetic bone marrow
Durgin et al. Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase
Cribioli et al. Enforcing GLUT3 expression in CD8+ T cells improves fitness and tumor control by promoting glucose uptake and energy storage
WO2023154904A3 (en) Compositions and methods for treating acute myeloid leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753731

Country of ref document: EP

Kind code of ref document: A2